<![CDATA[Hitting Hard and Early: Using Radioligand Therapy Earlier in mHSPC]]>

Conferencelutetium-177-PSMA-617Positive

AI Analysis

Summary

Dr. Fred Saad discussed clinical benefits of using lutetium-177-PSMA-617 earlier in metastatic hormone-sensitive prostate cancer treatment to delay progression to metastatic castration-resistant prostate cancer.

Importance:2/10

Sentiment:

0.30

radioligand therapyprostate cancermHSPCmCRPCPSMA-617clinical discussion

Related Companies

$NVS

Read the original article

Published by Cancer Network on June 3, 2026 2:00 PM

Read Original